论文部分内容阅读
目的探讨晚期肺癌患者外周血中淋巴细胞亚型表面程序性死亡受体1(PD-1)的表达水平。方法 30例晚期肺癌患者,采用流式细胞仪检测外周血中CD4+、CD8+、CD4+/CD8+、CD4+CD25+T细胞(调节性T细胞,Tregs)及CD8+T细胞表面PD-1(CD8+CD279+T)百分比,并与30例健康人的血液标本进行对比。结果与健康人比较,晚期肺癌患者CD4+及CD4+/CD8+T细胞水平有所降低,但差异无统计学意义(P>0.05);晚期肺癌患者CD8+T细胞水平为(27.70±12.87)%,CD8+CD279+T细胞水平为(2.03±1.35)%较健康人的(22.67±5.88)%、(1.26±0.83)%显著升高,差异有统计学意义(P<0.05);晚期肺癌患者CD4+CD25+T细胞数量(2.01±1.26)%显著高于健康人(0.98±0.55)%,差异有统计学意义(P<0.05)。结论晚期肺癌外周血CD4+CD25+T细胞数量显著高于健康人。
Objective To investigate the expression of PD-1 on peripheral blood lymphocytes in patients with advanced lung cancer. Methods Thirty patients with advanced lung cancer were enrolled in this study. Flow cytometry was used to detect the expression of CD8 +, CD8 +, CD4 + / CD8 +, CD4 + CD25 + T cells (Tregs) and CD8 + CD279 + T) percentage, and with 30 healthy blood samples were compared. Results The levels of CD4 + and CD4 + / CD8 + T cells in patients with advanced lung cancer were significantly lower than those in patients with advanced lung cancer (P> 0.05). The levels of CD8 + T cells in patients with advanced lung cancer were (27.70 ± 12.87)%, The level of CD8 + CD279 + T cells in patients with advanced lung cancer was (2.03 ± 1.35)% and significantly higher than that in healthy subjects (22.67 ± 5.88)% and (1.26 ± 0.83)%, respectively + CD25 + T cells (2.01 ± 1.26)% was significantly higher than that of healthy people (0.98 ± 0.55)%, the difference was statistically significant (P <0.05). Conclusions The number of CD4 + CD25 + T cells in peripheral blood of patients with advanced lung cancer is significantly higher than that of healthy people.